Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
638-23-3
Molecular formula
C5H9NO4S
Molecular weight
179.2 g/mol
Drug class
Mucolytic and mucoregulator (S-carboxymethyl-L-cysteine)
Mechanism of action
Modifies the composition and amount of respiratory mucus glycoproteins, including the acid-to-neutral glycoprotein ratio, and reduces goblet-cell hyperplasia; this helps restore more normal mucus characteristics in hypersecretory respiratory disorders.
Indications / reported uses
Management of respiratory disorders characterised by abnormal or excessive mucus, such as chronic bronchitis and other product-specified respiratory conditions
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Carbocisteine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Carbocisteine Permitted Daily Exposure (PDE) report (the Carbocisteine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Carbocisteine Occupational Exposure Limit (OEL) report (the Carbocisteine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.